Discovery and SAR of aryl hydroxy pyrimidinones as potent small molecule agonists of the GPCR APJ.

[1]  J. Vederas,et al.  Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents. , 2019, European journal of medicinal chemistry.

[2]  Katarzyna Pietraszek-Gremplewicz,et al.  The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer , 2018, Front. Physiol..

[3]  J. Vederas,et al.  Synthetic Modification within the "RPRL" Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation. , 2017, Journal of medicinal chemistry.

[4]  K. Bortoff,et al.  Discovery of a novel small molecule agonist scaffold for the APJ receptor. , 2016, Bioorganic & medicinal chemistry.

[5]  R. Snyder,et al.  Identifying structural determinants of potency for analogs of apelin-13: integration of C-terminal truncation with structure-activity. , 2014, Bioorganic & medicinal chemistry.

[6]  L. Huson,et al.  Sustained Cardiovascular Actions of APJ Agonism During Renin–Angiotensin System Activation and in Patients With Heart Failure , 2013, Circulation. Heart failure.

[7]  G. Akita,et al.  Cardiovascular effects of a PEGylated apelin , 2012, Peptides.

[8]  R. Leduc,et al.  Elucidation of the Structure–Activity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding, Signaling, and Plasma Stability , 2012, ChemMedChem.

[9]  O. Hucke,et al.  Assessing atropisomer axial chirality in drug discovery and development. , 2011, Journal of medicinal chemistry.

[10]  R. Glen,et al.  Exploring the ‘RPRL’ Motif of Apelin‐13 through Molecular Simulation and Biological Evaluation of Cyclic Peptide Analogues , 2010, ChemMedChem.

[11]  J. Galzi,et al.  Identification and pharmacological properties of E339–3D6, the first nonpeptidic apelin receptor agonist , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  D. Newby,et al.  Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure , 2010, Circulation.

[13]  E. Trinquet,et al.  HTRF: A Technology Tailored for Drug Discovery –A Review of Theoretical Aspects and Recent Applications , 2009, Current chemical genomics.

[14]  D. Webb,et al.  Vascular effects of apelin in vivo in man. , 2008, Journal of the American College of Cardiology.

[15]  Rob W. W. Hooft,et al.  Determination of absolute structure using Bayesian statistics on Bijvoet differences , 2008, Journal of applied crystallography.

[16]  J. Rysä,et al.  Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility , 2002, Circulation research.

[17]  S. Hinuma,et al.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. , 1998, Biochemical and biophysical research communications.

[18]  H. Heng,et al.  A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. , 1993, Gene.

[19]  H. Takeshima,et al.  Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[20]  E. Ashley,et al.  The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. , 2005, Cardiovascular research.